Angiotensin-receptor blockers (ARBs), drugs commonly used in the treatment of high blood pressure, heart failure, and kidney damage due to diabetes, are associated with a modestly increased risk of developing cancer. Although the limited data makes it impossible to calculate the exact cancer risk associated with each individual drug, these findings demand further investigation, concludes an article published online in The Lancet Oncology. ARBs work by blocking the receptors for angiotensin II,...

Photo by © ASCO/Todd Buchanan 2010 Over 32,000 physicians, researchers and healthcare professionals from over 100 countries attended the 2010 American Society of Clinical Oncolgy Annual Meeting, which was held at McCormick Place and featured the latest innovations in cancer research, quality, practice and technology. Breaking News Bevacizumab Added to Chemotherapy Increases PFS in Ovarian, Related Cancers CHICAGO (EGMN) – Progression-free survival in women with advanced ovarian or...